GB201516905D0 - Treatment of Neurodegenerative diseases - Google Patents

Treatment of Neurodegenerative diseases

Info

Publication number
GB201516905D0
GB201516905D0 GBGB1516905.5A GB201516905A GB201516905D0 GB 201516905 D0 GB201516905 D0 GB 201516905D0 GB 201516905 A GB201516905 A GB 201516905A GB 201516905 D0 GB201516905 D0 GB 201516905D0
Authority
GB
United Kingdom
Prior art keywords
treatment
neurodegenerative diseases
neurodegenerative
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1516905.5A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BenevolentAI Bio Ltd
Original Assignee
Stratified Medical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stratified Medical Ltd filed Critical Stratified Medical Ltd
Priority to GBGB1516905.5A priority Critical patent/GB201516905D0/en
Publication of GB201516905D0 publication Critical patent/GB201516905D0/en
Priority to JP2018516056A priority patent/JP6893917B2/ja
Priority to EP16775842.4A priority patent/EP3352759A1/en
Priority to KR1020187010855A priority patent/KR20180056695A/ko
Priority to CN201680056062.1A priority patent/CN108025005A/zh
Priority to CA2999390A priority patent/CA2999390A1/en
Priority to PCT/GB2016/052970 priority patent/WO2017051188A1/en
Priority to BR112018005855A priority patent/BR112018005855A2/pt
Priority to EA201890647A priority patent/EA201890647A1/ru
Priority to MX2018003619A priority patent/MX2018003619A/es
Priority to AU2016329005A priority patent/AU2016329005A1/en
Priority to MA042930A priority patent/MA42930A/fr
Priority to US15/762,657 priority patent/US20180263992A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/49—Cinchonan derivatives, e.g. quinine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GBGB1516905.5A 2015-09-24 2015-09-24 Treatment of Neurodegenerative diseases Ceased GB201516905D0 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
GBGB1516905.5A GB201516905D0 (en) 2015-09-24 2015-09-24 Treatment of Neurodegenerative diseases
US15/762,657 US20180263992A1 (en) 2015-09-24 2016-09-23 Treatment of neurodegenerative diseases
PCT/GB2016/052970 WO2017051188A1 (en) 2015-09-24 2016-09-23 Treatment of neurodegenerative diseases
EP16775842.4A EP3352759A1 (en) 2015-09-24 2016-09-23 Treatment of neurodegenerative diseases
KR1020187010855A KR20180056695A (ko) 2015-09-24 2016-09-23 신경퇴행성 질병의 치료
CN201680056062.1A CN108025005A (zh) 2015-09-24 2016-09-23 神经退行性疾病的治疗
CA2999390A CA2999390A1 (en) 2015-09-24 2016-09-23 Treatment of neurodegenerative diseases
JP2018516056A JP6893917B2 (ja) 2015-09-24 2016-09-23 神経変性疾患の処置
BR112018005855A BR112018005855A2 (pt) 2015-09-24 2016-09-23 tratamento de doenças neurodegenerativas
EA201890647A EA201890647A1 (ru) 2015-09-24 2016-09-23 Лечение нейродегенеративных заболеваний
MX2018003619A MX2018003619A (es) 2015-09-24 2016-09-23 Tratamiento de enfermedades neurodegenerativas.
AU2016329005A AU2016329005A1 (en) 2015-09-24 2016-09-23 Treatment of neurodegenerative diseases
MA042930A MA42930A (fr) 2015-09-24 2016-09-23 Traitement de maladies neurodégénératives

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1516905.5A GB201516905D0 (en) 2015-09-24 2015-09-24 Treatment of Neurodegenerative diseases

Publications (1)

Publication Number Publication Date
GB201516905D0 true GB201516905D0 (en) 2015-11-11

Family

ID=54544061

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1516905.5A Ceased GB201516905D0 (en) 2015-09-24 2015-09-24 Treatment of Neurodegenerative diseases

Country Status (13)

Country Link
US (1) US20180263992A1 (https=)
EP (1) EP3352759A1 (https=)
JP (1) JP6893917B2 (https=)
KR (1) KR20180056695A (https=)
CN (1) CN108025005A (https=)
AU (1) AU2016329005A1 (https=)
BR (1) BR112018005855A2 (https=)
CA (1) CA2999390A1 (https=)
EA (1) EA201890647A1 (https=)
GB (1) GB201516905D0 (https=)
MA (1) MA42930A (https=)
MX (1) MX2018003619A (https=)
WO (1) WO2017051188A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016077595A1 (en) 2014-11-12 2016-05-19 The General Hospital Corporation Methods for treating neurodegenerative diseases
GB201714307D0 (en) * 2017-09-06 2017-10-18 Benevolentai Ltd Treatment of neurodegenerative diseases
GB201714311D0 (en) * 2017-09-06 2017-10-18 Benevolentai Ltd Treatment of neurodegenerative diseases
GB201714303D0 (en) * 2017-09-06 2017-10-18 Benevolentai Ltd Treatment of neurodegenerative diseases
GB201714316D0 (en) * 2017-09-06 2017-10-18 Benevolentai Ltd Treatement of neurodegenerative diseases
CN108853111B (zh) * 2018-08-07 2020-06-05 浙江大学 一种组合物在制备治疗吉非替尼肝脏毒性药物中的应用
US12441707B2 (en) 2019-12-30 2025-10-14 Tyra Biosciences, Inc. Indazole compounds
CN114099509B (zh) * 2020-08-26 2023-12-08 长庚大学 一种酪氨酸激酶抑制剂在制造用以治疗因炎性体激活所致相关疾病的药物中的用途
CN113694047A (zh) * 2021-08-31 2021-11-26 杭州师范大学 β-石竹烯在制备抗肿瘤药物中的应用
WO2025152803A1 (zh) * 2024-01-17 2025-07-24 四川大学 一种靶向traf6的多肽及其用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US257403A (en) * 1882-05-02 Electric lighting apparatus
US62342A (en) * 1867-02-26 Improved tool for the manufacture of paper bags
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US20030232741A1 (en) * 2002-05-06 2003-12-18 Washington University Methods of treatment of glaucoma and other conditions mediated by NOS-2 expression via inhibition of the EGFR pathway
JP4328500B2 (ja) * 2002-07-25 2009-09-09 独立行政法人農業・食品産業技術総合研究機構 中枢神経細胞突起再生剤及びその薬理作用を有する高機能性製品
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
AU2004230841A1 (en) * 2003-04-03 2004-10-28 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
CA2555457C (en) * 2004-02-09 2012-08-21 Mitsubishi Pharma Corporation A novel therapeutic agent for amyotrophic lateral sclerosis (als) or diseases caused by als
KR101313702B1 (ko) * 2005-02-03 2013-10-04 와이어쓰 제피티니브 및/또는 에를로티니브 내성암 치료용 약제학적 조성물
US7449442B2 (en) * 2005-07-12 2008-11-11 Children's Medical Center Corporation EGFR inhibitors promote axon regeneration
JP2008061505A (ja) * 2006-09-04 2008-03-21 Hisamitsu Pharmaceut Co Inc 筋萎縮性側索硬化症の治療剤のスクリーニング方法
US8993615B2 (en) * 2008-08-08 2015-03-31 The Johns Hopkins University Compositions and methods for treatment of neurodegenerative disease
BR112012002333A2 (pt) * 2009-08-06 2017-07-18 Neuraltus Pharmaceuticals Inc método de reduzir os efeitos colaterais e método de potencializar o efeito de um imunomodulador administrado a um sujeito que dele necessita; métodos para tratar doença associada com excesso de ativação de monócitos para macrófagos ativados, diabetes tipo ii ou complicações relacionadas, doença associada com a migração de monócitos ou macrófagos ativados, doença associada a excesso de produção de scd14 e/ou scd163 por macrófagos ativados; composto de cloreto de sódio; composição farmacêutica; método para diagnosticar uma doença relacionada com macrófagos em um sujeito; e método para determinar a eficácia do tratamento com um agente oxidante para uma doença relacionada a macrófagos em um sujeito.
EP3011970A3 (en) * 2009-10-22 2016-06-08 F. Hoffmann-La Roche AG Modulation of axon degeneration
JP6464084B2 (ja) * 2012-07-27 2019-02-06 イズミ テクノロジー，エルエルシー 排出阻害剤およびこれを用いる治療法

Also Published As

Publication number Publication date
US20180263992A1 (en) 2018-09-20
MA42930A (fr) 2018-08-01
EA201890647A1 (ru) 2018-09-28
CN108025005A (zh) 2018-05-11
AU2016329005A1 (en) 2018-04-19
JP2018534259A (ja) 2018-11-22
EP3352759A1 (en) 2018-08-01
WO2017051188A1 (en) 2017-03-30
JP6893917B2 (ja) 2021-06-23
MX2018003619A (es) 2018-08-01
BR112018005855A2 (pt) 2018-10-16
CA2999390A1 (en) 2017-03-30
KR20180056695A (ko) 2018-05-29

Similar Documents

Publication Publication Date Title
SMT201900172T1 (it) Ammino triazoli sostituiti utili come inibitori della chitinasi umana
IL269106A (en) Methods for the treatment of neurodegenerative diseases
ZA201903003B (en) Treatment of neurological diseases
PT3273955T (pt) Tratamento de doenças respiratórias
GB201516905D0 (en) Treatment of Neurodegenerative diseases
IL285882A (en) Medicinal uses for l–4–chlorokynurenine
GB201412578D0 (en) Treatment of neurological diseases
IL253847A0 (en) Methods of treating diseases
IL254155A0 (en) pain treatment
GB201714307D0 (en) Treatment of neurodegenerative diseases
PL3182980T3 (pl) Leczenie chorób niedoboru glikozylacji
HUE062134T2 (hu) Mitokondriális betegségek kezelése
GB201714316D0 (en) Treatement of neurodegenerative diseases
GB201412010D0 (en) Treatment of hypertransaminasemia
GB201714303D0 (en) Treatment of neurodegenerative diseases
GB201714311D0 (en) Treatment of neurodegenerative diseases
GB201512139D0 (en) Methods of treatment
GB201514729D0 (en) Treatment of haemorrhoids
GB201704666D0 (en) Treatment of neurodegenerative diseases
GB201517565D0 (en) Treatment of genetic diseases
GB201514909D0 (en) Treatment of autoimmune diseases
GB201621398D0 (en) Treatment of emt-associated disease
GB201504413D0 (en) Treatment of disease
SG10201913141UA (en) Treatment of alphavirus-induced inflammation
GB201604253D0 (en) Treatment of genetic diseases

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)